drugset / Trial / NCT01631487

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

NCT01631487

Phase 1 Completed 86 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of JNJ-39439335 in healthy Japanese and Caucasian adult male participants in Part 1, and in healthy Japanese adult male participants in Part 2.

Timeline

Start
2012-07
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MAVATREP Small molecule 10 mg Oral
Subject MAVATREP Small molecule 25 mg Oral
Subject MAVATREP Small molecule 50 mg Oral

Indications

No indication recorded.